René Rizzoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3131572/publications.pdf

Version: 2024-02-01

308 papers 39,374 citations

91 h-index

3334

188 g-index

341 all docs

341 does citations

times ranked

341

29370 citing authors

#	Article	IF	Citations
1	Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019, 48, 16-31.	1.6	6,824
2	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2013, 24, 23-57.	3.1	1,560
3	The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. New England Journal of Medicine, 2004, 350, 459-468.	27.0	1,465
4	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2019, 30, 3-44.	3.1	1,020
5	Critical Years and Stages of Puberty for Spinal and Femoral Bone Mass Accumulation during Adolescence*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 555-563.	3.6	1,006
6	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2008, 19, 399-428.	3.1	792
7	Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects Journal of Clinical Endocrinology and Metabolism, 1992, 75, 1060-1065.	3.6	661
8	Bone strength and its determinants. Osteoporosis International, 2003, 14, 13-18.	3.1	549
9	Protein Supplements Increase Serum Insulin-Like Growth Factor-I Levels and Attenuate Proximal Femur Bone Loss in Patients with Recent Hip Fracture. Annals of Internal Medicine, 1998, 128, 801.	3.9	517
10	Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone, 2010, 46, 294-305.	2.9	510
11	Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial Journal of Clinical Investigation, 1997, 99, 1287-1294.	8.2	497
12	Fibroblast Growth Factor-23 Relationship to Dietary Phosphate and Renal Phosphate Handling in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1519-1524.	3 . 6	481
13	Sarcopenia in daily practice: assessment and management. BMC Geriatrics, 2016, 16, 170.	2.7	468
14	Interpretation and use of FRAX in clinical practice. Osteoporosis International, 2011, 22, 2395-2411.	3.1	450
15	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	3.4	414
16	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology, 2008, 19, 420-432.	1.2	410
17	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	3.4	392
18	Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 2017, 28, 1817-1833.	3.1	381

#	Article	IF	Citations
19	Sarcopenia: burden and challenges for public health. Archives of Public Health, 2014, 72, 45.	2.4	317
20	Quality of Life in Sarcopenia and Frailty. Calcified Tissue International, 2013, 93, 101-120.	3.1	310
21	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. Calcified Tissue International, 2019, 105, 1-14.	3.1	295
22	Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency Journal of Clinical Investigation, 1997, 99, 1699-1703.	8.2	287
23	Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine, 2012, 367, 1714-1723.	27.0	285
24	Peak bone mass. Osteoporosis International, 1994, 4, S7-S13.	3.1	272
25	Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 2013, 29, 305-313.	1.9	266
26	Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis International, 2012, 23, 1839-1848.	3.1	258
27	Global dietary calcium intake among adults: a systematic review. Osteoporosis International, 2017, 28, 3315-3324.	3.1	249
28	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 34-43.	11.4	244
29	Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporosis International, 2013, 24, 1555-1566.	3.1	236
30	Benefits of oral protein supplementation in elderly patients with fracture of the proximal femur Journal of the American College of Nutrition, 1992, 11, 519-525.	1.8	229
31	Familial Resemblance for Bone Mineral Mass Is Expressed before Puberty1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 358-361.	3.6	224
32	Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis International, 2011, 22, 373-390.	3.1	220
33	Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. Journal of Bone and Mineral Research, 2011, 26, 242-251.	2.8	220
34	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1-12.	3.1	220
35	Osteoporosis, genetics and hormones. Journal of Molecular Endocrinology, 2001, 26, 79-94.	2.5	217
36	A prospective study on socioeconomic aspects of fracture of the proximal femur. Journal of Bone and Mineral Research, 1996, 11, 1935-1942.	2.8	214

#	Article	IF	Citations
37	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas, 2014, 79, 122-132.	2.4	213
38	Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 2016, 98, 1-17.	3.1	210
39	Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporosis International, 2015, 26, 2793-2802.	3.1	207
40	Survival and Potential Years of Life Lost After Hip Fracture in Men and Age-matched Women. Osteoporosis International, 2002, 13, 731-737.	3.1	198
41	Effect of Music-Based Multitask Training on Gait, Balance, and Fall Risk in Elderly People. Archives of Internal Medicine, 2011, 171, 525-33.	3.8	198
42	Tools in the Assessment of Sarcopenia. Calcified Tissue International, 2013, 93, 201-210.	3.1	197
43	Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 2002, 17, 1988-1996.	2.8	195
44	Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry. Journal of Bone and Mineral Research, 1992, 7, 311-316.	2.8	194
45	Gain in bone mineral mass in prepubertal girls 3–5 years after discontinuation of calcium supplementation: a follow-up study. Lancet, The, 2001, 358, 1208-1212.	13.7	191
46	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone, 2008, 42, 841-847.	2.9	189
47	Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?. Bone, 2009, 45, 843-852.	2.9	189
48	Increasing Occurrence of Atypical Femoral Fractures Associated With Bisphosphonate Use. Archives of Internal Medicine, 2012, 172, 930-6.	3.8	187
49	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1855.	7.4	180
50	Efficacy of risedronate on clinical vertebral fractures within six months. Current Medical Research and Opinion, 2004, 20, 433-439.	1.9	171
51	Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporosis International, 2009, 20, 1131-1140.	3.1	171
52	Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International, 2011, 89, 91-104.	3.1	170
53	A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis International, 2003, 14, 2-12.	3.1	169
54	Dairy products, yogurts, and bone health. American Journal of Clinical Nutrition, 2014, 99, 1256S-1262S.	4.7	168

#	Article	IF	CITATIONS
55	Validation of the SarQoL®, a specific healthâ€related quality of life questionnaire for Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 238-244.	7.3	166
56	Incidence of hip fracture over a 10-year period (1991–2000): Reversal of a secular trend. Bone, 2007, 40, 1284-1289.	2.9	164
57	Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 2017, 28, 1507-1529.	3.1	160
58	An Osteoporosis Clinical Pathway for the Medical Management of Patients with Low-Trauma Fracture. Osteoporosis International, 2002, 13, 450-455.	3.1	159
59	Relationship between bone mineral density and dietary intakes in the elderly. Osteoporosis International, 1993, 3, 242-248.	3.1	158
60	Does the Mini Nutritional Assessment predict hospitalization outcomes in older people?. Age and Ageing, 2001, 30, 221-226.	1.6	155
61	Interaction between Calcium Intake and Menarcheal Age on Bone Mass Gain: An Eight-Year Follow-Up Study from Prepuberty to Postmenarche. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 44-51.	3.6	154
62	Childhood Fractures Are Associated With Decreased Bone Mass Gain During Puberty: An Early Marker of Persistent Bone Fragility?. Journal of Bone and Mineral Research, 2005, 21, 501-507.	2.8	147
63	Strontium Ranelate Treatment Improves Trabecular and Cortical Intrinsic Bone Tissue Quality, a Determinant of Bone Strength. Journal of Bone and Mineral Research, 2007, 22, 1419-1425.	2.8	147
64	Antidepressant medications and osteoporosis. Bone, 2012, 51, 606-613.	2.9	144
65	Quality of life assessment in musculo-skeletal health. Aging Clinical and Experimental Research, 2018, 30, 413-418.	2.9	144
66	Vitamin D Receptor Gene Start Codon Polymorphisms (⟨i⟩Fok⟨/i⟩I) and Bone Mineral Density: Interaction with Age, Dietary Calcium, and 3′-End Region Polymorphisms. Journal of Bone and Mineral Research, 1998, 13, 925-930.	2.8	142
67	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2949-2957.	3.6	131
68	Protein Undernutrition-Induced Bone Loss Is Associated with Decreased IGF-I Levels and Estrogen Deficiency. Journal of Bone and Mineral Research, 2010, 15, 683-690.	2.8	130
69	The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporosis International, 2017, 28, 447-462.	3.1	130
70	Glucocorticoid-induced osteoporosis: who to treat with what agent?. Nature Reviews Rheumatology, 2015, 11, 98-109.	8.0	129
71	Asynchrony between the rates of standing height gain and bone mass accumulation during puberty. Osteoporosis International, 1997, 7, 525-532.	3.1	128
72	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	3.1	126

#	Article	IF	Citations
73	SCOPE: a scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2013, 8, 144.	2.4	125
74	The role of calcium and vitamin D in the management of osteoporosis. Bone, 2008, 42, 246-249.	2.9	124
75	Strontium ranelate improves implant osseointegration. Bone, 2010, 46, 1436-1441.	2.9	124
76	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2012, 27, 211-218.	2.8	124
77	Arginine increases insulin-like growth factor-I production and collagen synthesis in osteoblast-like cells. Bone, 1998, 23, 103-109.	2.9	117
78	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 2016, 33, 75-85.	2.7	116
79	Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone, 1988, 9, 123-130.	2.9	115
80	Dietary Protein and Bone Health. Journal of Bone and Mineral Research, 2004, 19, 527-531.	2.8	115
81	Dietary Protein Restriction Lowers Plasma Insulin-Like Growth Factor I (IGF-I), Impairs Cortical Bone Formation, and Induces Osteoblastic Resistance to IGF-I in Adult Female Rats ¹ . Endocrinology, 2000, 141, 3149-3155.	2.8	114
82	Cancer-associated bone disease. Osteoporosis International, 2013, 24, 2929-2953.	3.1	113
83	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International, 2017, 28, 767-774.	3.1	113
84	Gene-Environment Interactions in the Skeletal Response to Nutrition and Exercise during Growth. , 2007, 51 , $64-80$.		111
85	Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper. Calcified Tissue International, 2012, 90, 343-353.	3.1	111
86	Peripheral skeleton bone strength is positively correlated with total and dairy protein intakes in healthy postmenopausal women. American Journal of Clinical Nutrition, 2017, 105, 513-525.	4.7	107
87	FRAX \hat{A}^{o} assessment of osteoporotic fracture probability in Switzerland. Osteoporosis International, 2010, 21, 381-389.	3.1	106
88	Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified Tissue International, 2019, 104, 235-238.	3.1	105
89	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Research Reviews, 2019, 55, 100946.	10.9	103
90	Determinants of Peak Bone Mass and Mechanisms of Bone Loss. Osteoporosis International, 1999, 9, S17-S23.	3.1	102

#	Article	IF	Citations
91	Skeletal Site Selectivity in the Effects of Calcium Supplementation on Areal Bone Mineral Density Gain: A Randomized, Double-Blind, Placebo-Controlled Trial in Prepubertal Boys. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3342-3349.	3.6	101
92	Vitamin D Supplementation during Infancy Is Associated with Higher Bone Mineral Mass in Prepubertal Girls1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4541-4544.	3.6	99
93	Benefits and safety of dietary protein for bone healthâ€"an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International, 2018, 29, 1933-1948.	3.1	98
94	Nutritional intake and bone health. Lancet Diabetes and Endocrinology, the, 2021, 9, 606-621.	11.4	98
95	Dietary Protein Deficiency Induces Osteoporosis in Aged Male Rats. Journal of Bone and Mineral Research, 2000, 15, 1555-1563.	2.8	95
96	The role of dual energy X-rayabsorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. American Journal of Medicine, 1995, 98, 33S-36S.	1.5	92
97	Nutrition: its role in bone health. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 813-829.	4.7	91
98	Dietary Protein and Bone Health: Roles of Amino Acid–Sensing Receptors in the Control of Calcium Metabolism and Bone Homeostasis. Annual Review of Nutrition, 2008, 28, 131-155.	10.1	91
99	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	2.9	91
100	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 2016, 7, 243-246.	2.8	90
101	Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age and Ageing, 2015, 44, 960-966.	1.6	89
102	Protein Intake and Bone Growth. Applied Physiology, Nutrition, and Metabolism, 2001, 26, S153-S166.	1.7	88
103	Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporosis International, 1996, 6, 219-227.	3.1	87
104	High-Protein Intake Enhances the Positive Impact of Physical Activity on BMC in Prepubertal Boys. Journal of Bone and Mineral Research, 2008, 23, 131-142.	2.8	86
105	Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3873-3883.	3.6	85
106	Protein intake, IGF-1 and osteoporosis. Osteoporosis International, 1997, 7, 36-42.	3.1	84
107	Official Positions for FRAX® Clinical Regarding International Differences. Journal of Clinical Densitometry, 2011, 14, 240-262.	1.2	84
108	International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. European Journal of Cancer, 2007, 43, 852-858.	2.8	83

#	Article	IF	Citations
109	Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporosis International, 2012, 23, 2567-2576.	3.1	83
110	Epidemiology and economic burden of osteoporosis in Switzerland. Archives of Osteoporosis, 2014, 9, 187.	2.4	81
111	The position of strontium ranelate in today's management of osteoporosis. Osteoporosis International, 2015, 26, 1667-1671.	3.1	81
112	Evaluation of Radius Microstructure and Areal Bone Mineral Density Improves Fracture Prediction in Postmenopausal Women. Journal of Bone and Mineral Research, 2018, 33, 328-337.	2.8	81
113	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. European Journal of Endocrinology, 2019, 180, P1-P22.	3.7	81
114	Low Lean Mass Predicts Incident Fractures Independently From FRAX: a Prospective Cohort Study of Recent Retirees. Journal of Bone and Mineral Research, 2016, 31, 2048-2056.	2.8	80
115	Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronate therapy. Bone, 1994, 15, 193-198.	2.9	77
116	Management of Glucocorticoid-Induced Osteoporosis. Calcified Tissue International, 2012, 91, 225-243.	3.1	77
117	Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Osteoporosis International, 2012, 23, 305-315.	3.1	76
118	Nutritional aspects of bone health. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 795-808.	4.7	76
119	A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. Aging Clinical and Experimental Research, 2016, 28, 797-803.	2.9	7 5
120	Dietary Essential Amino Acid Supplements Increase Bone Strength by Influencing Bone Mass and Bone Microarchitecture in Ovariectomized Adult Rats Fed an Isocaloric Low-Protein Diet. Journal of Bone and Mineral Research, 2002, 17, 1264-1272.	2.8	73
121	Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Archives of Osteoporosis, 2017, 12, 1.	2.4	72
122	Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporosis International, 1995, 5, 39-46.	3.1	71
123	\hat{l}^2 -Arrestin2 Regulates the Differential Response of Cortical and Trabecular Bone to Intermittent PTH in Female Mice. Journal of Bone and Mineral Research, 2004, 20, 635-643.	2.8	71
124	Influence of Age at Menarche on Forearm Bone Microstructure in Healthy Young Women. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2594-2601.	3.6	71
125	Management of osteoporosis of the oldest old. Osteoporosis International, 2014, 25, 2507-2529.	3.1	71
126	Effect of a general school-based physical activity intervention on bone mineral content and density: A cluster-randomized controlled trial. Bone, 2011, 48, 792-797.	2.9	70

#	Article	IF	CITATIONS
127	Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 65-99.	2.7	70
128	Management of osteoporosis in the elderly. Current Medical Research and Opinion, 2009, 25, 2373-2387.	1.9	69
129	Deleterious Effect of Late Menarche on Distal Tibia Microstructure in Healthy 20-Year-Old and Premenopausal Middle-Aged Women. Journal of Bone and Mineral Research, 2009, 24, 144-152.	2.8	69
130	Fractures during Childhood and Adolescence in Healthy Boys: Relation with Bone Mass, Microstructure, and Strength. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3134-3142.	3.6	69
131	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International. 2019. 30. 2155-2165.	3.1	69
132	Nutritional strategies for maintaining muscle mass and strength from middle age to later life: A narrative review. Maturitas, 2020, 132, 57-64.	2.4	69
133	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International. 2019. 30. 45-57.	3.1	67
134	A thymoma as a cause of true ectopic hyperparathyroidism Journal of Clinical Endocrinology and Metabolism, 1994, 79, 912-915.	3.6	66
135	Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatology International, 2010, 30, 1341-1348.	3.0	66
136	Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporosis International, 2012, 23, 2579-2589.	3.1	66
137	Protein intake and bone disorders in the elderly. Joint Bone Spine, 2001, 68, 383-392.	1.6	65
138	A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement. Journal of Nutrition, Health and Aging, 2016, 20, 647-652.	3.3	65
139	Intrinsic bone tissue properties in adult rat vertebrae: modulation by dietary protein. Bone, 2005, 36, 134-141.	2.9	64
140	Postmenopausal osteoporosis: Assessment and management. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 739-757.	4.7	64
141	Weight-bearing bones are more sensitive to physical exercise in boys than in girls during pre- and early puberty: a cross-sectional study. Osteoporosis International, 2008, 19, 1749-1758.	3.1	63
142	Fractures in Healthy Females Followed from Childhood to Early Adulthood Are Associated with Later Menarcheal Age and with Impaired Bone Microstructure at Peak Bone Mass. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4174-4181.	3.6	63
143	A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International, 2012, 23, 213-221.	3.1	62
144	Vitamin D supplementation: upper limit for safety revisited?. Aging Clinical and Experimental Research, 2021, 33, 19-24.	2.9	62

#	Article	IF	CITATIONS
145	Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporosis International, 2010, 21, 723-732.	3.1	61
146	Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 2014, 25, 2533-2543.	3.1	61
147	Epidemiology of fractures of the proximal femur in Geneva: Incidence, clinical and social aspects. Osteoporosis International, 1991, 2, 42-47.	3.1	60
148	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60
149	Oligo-amenorrheic long-distance runners may lose more bone in spine than in femur. Medicine and Science in Sports and Exercise, 2001, 33, 15-21.	0.4	59
150	Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 7-14.	2.7	59
151	Nutrition and Bone Health in Women after the Menopause. Women's Health, 2014, 10, 599-608.	1.5	58
152	Effects of Fermented Milk Products on Bone. Calcified Tissue International, 2018, 102, 489-500.	3.1	57
153	Effects of vitamin D in the elderly population: current status and perspectives. Archives of Public Health, 2014, 72, 32.	2.4	56
154	Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2018, 30, 111-117.	2.9	56
155	Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study. International Journal of Clinical Practice, 2006, 60, 1013-1019.	1.7	54
156	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine, 2015, 50, 12-26.	2.3	53
157	The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 2017, 8, 75646-75663.	1.8	53
158	MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of vitamin D. European Journal of Endocrinology, 2018, 179, R239-R259.	3.7	53
159	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017. 56. 245-261.	2.3	52
160	Life-course approach to nutrition. Osteoporosis International, 2015, 26, 2723-2742.	3.1	51
161	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 2019, 105, 109-124.	3.1	51
162	A rapid self-administered food frequency questionnaire for the evaluation of dietary protein intake. Clinical Nutrition, 2005, 24, 768-774.	5.0	50

#	Article	IF	Citations
163	Bisphosphonates for post-menopausal osteoporosis: are they all the same?. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 281-300.	0.5	50
164	Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Archives of Osteoporosis, 2016, 11, 37.	2.4	50
165	Are Probiotics the New Calcium and Vitamin D for Bone Health?. Current Osteoporosis Reports, 2020, 18, 273-284.	3.6	50
166	Hormonal regulation of biomineralization. Nature Reviews Endocrinology, 2021, 17, 261-275.	9.6	50
167	A thymoma as a cause of true ectopic hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 912-915.	3.6	49
168	Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats. Journal of Bone and Mineral Research, 1989, 4, 759-765.	2.8	48
169	Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture. Clinical Nutrition, 2010, 29, 78-83.	5.0	48
170	Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. Journal of Bone and Mineral Research, 1993, 8, 1491-1498.	2.8	47
171	Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Annals of Oncology, 2019, 30, 908-920.	1.2	47
172	Fermented dairy products consumption is associated with attenuated cortical bone loss independently of total calcium, protein, and energy intakes in healthy postmenopausal women. Osteoporosis International, 2018, 29, 1771-1782.	3.1	46
173	Impact of whole dairy matrix on musculoskeletal health and aging–current knowledge and research gaps. Osteoporosis International, 2020, 31, 601-615.	3.1	46
174	Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clinical and Experimental Research, 2021, 33, 3-17.	2.9	46
175	Regulation of parathyroid hormone-related protein production in a human lung squamous cell carcinoma line. Journal of Endocrinology, 1994, 143, 333-341.	2.6	44
176	Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporosis International, 2008, 19, 1741-1747.	3.1	43
177	Socioeconomic and living conditions are determinants of hip fracture incidence and age occurrence among community-dwelling elderly. Osteoporosis International, 2011, 22, 647-653.	3.1	43
178	Nutritional influence on bone: role of gut microbiota. Aging Clinical and Experimental Research, 2019, 31, 743-751.	2.9	43
179	Denosumab. Nature Reviews Drug Discovery, 2010, 9, 591-592.	46.4	42
180	Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius. Bone, 2013, 55, 377-383.	2.9	42

#	Article	IF	Citations
181	Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nature Reviews Endocrinology, 2022, 18, 366-384.	9.6	42
182	Prior ankle fractures in postmenopausal women are associated with low areal bone mineral density and bone microstructure alterations. Osteoporosis International, 2015, 26, 2147-2155.	3.1	40
183	English translation and validation of the SarQoL (sup) \hat{A}^{\otimes} (sup), a quality of life questionnaire specific for sarcopenia. Age and Ageing, 2017, 46, 271-276.	1.6	40
184	Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clinical and Experimental Research, 2019, 31, 15-17.	2.9	40
185	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 2020, 80, 1537-1552.	10.9	40
186	Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3545-3550.	3.6	39
187	Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 2012, 28, 475-491.	1.9	39
188	Bone management in hematologic stem cell transplant recipients. Osteoporosis International, 2018, 29, 2597-2610.	3.1	39
189	High extracellular calcium increases the production of a parathyroid hormone-like activity by cultured leydig tumor cells associated with humoral hypercalcemia. Journal of Bone and Mineral Research, 1989, 4, 839-844.	2.8	38
190	Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporosis International, 2013, 24, 139-150.	3.1	38
191	Zinc increases the effects of essential amino acids-whey protein supplements in frail elderly. Journal of Nutrition, Health and Aging, 2009, 13, 491-497.	3.3	37
192	Adverse drug reactions to osteoporosis treatments. Expert Review of Clinical Pharmacology, 2011, 4, 593-604.	3.1	37
193	Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronate. International Journal of Cancer, 1992, 50, 706-712.	5.1	36
194	Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia. Bone, 1991, 12, 47-56.	2.9	35
195	Influence of the Disaccharide Lactitol on Intestinal Absorption and Body Retention of Calcium in Rats. Journal of Nutrition, 1988, 118, 793-795.	2.9	33
196	Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 2022, 34, 695-714.	2.9	33
197	Pregnancy-associated osteoporosis. Lancet, The, 1996, 347, 1274-1276.	13.7	32
198	Defective Implant Osseointegration Under Protein Undernutrition: Prevention by PTH or Pamidronate. Journal of Bone and Mineral Research, 2007, 22, 1526-1533.	2.8	32

#	Article	IF	Citations
199	Continuous treatment with odanacatib for up to 8Âyears in postmenopausal women with low bone mineral density: a phase 2 study. Osteoporosis International, 2016, 27, 2099-2107.	3.1	32
200	Phosphate wasting disorders in adults. Osteoporosis International, 2018, 29, 2369-2387.	3.1	32
201	East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clinical and Experimental Research, 2019, 31, 1351-1373.	2.9	32
202	Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. Biochemical Journal, 1986, 237, 447-454.	3.7	31
203	Post-fracture management of patients with hip fracture: a perspective. Current Medical Research and Opinion, 2008, 24, 2841-2851.	1.9	31
204	PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet. Osteoporosis International, 2010, 21, 957-967.	3.1	30
205	Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta—a case report. Monthly Notices of the Royal Astronomical Society: Letters, 2012, 83, 548-550.	3.3	30
206	Nutrition and bone health: turning knowledge and beliefs into healthy behaviour. Current Medical Research and Opinion, 2014, 30, 131-141.	1.9	30
207	Long-Term Exercise in Older Adults: 4-Year Outcomes of Music-Based Multitask Training. Calcified Tissue International, 2014, 95, 393-404.	3.1	30
208	Dairy products and bone health. Aging Clinical and Experimental Research, 2022, 34, 9-24.	2.9	29
209	High Bone Density in Adolescents With Obesity Is Related to Fat Mass and Serum Leptin Concentrations. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 723-728.	1.8	28
210	Pro-inflammatory dietary pattern is associated with fractures in women: an eight-year longitudinal cohort study. Osteoporosis International, 2018, 29, 143-151.	3.1	28
211	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. Contemporary Clinical Trials, 2021, 100, 106124.	1.8	28
212	Parathyroid hormone-related protein and hypercalcemia in pancreatic neuro-endocrine tumors. International Journal of Cancer, 1990, 46, 394-398.	5.1	27
213	3-year follow-up results of bone mineral content and density after a school-based physical activity randomized intervention trial. Bone, 2013, 55, 16-22.	2.9	27
214	Tracking of Environmental Determinants of Bone Structure and Strength Development in Healthy Boys: An Eight-Year Follow Up Study on the Positive Interaction Between Physical Activity and Protein Intake From Prepuberty to Mid-Late Adolescence. Journal of Bone and Mineral Research, 2014, 29, 2182-2192.	2.8	27
215	Additive Genetic Effects on Circulating Periostin Contribute to the Heritability of Bone Microstructure. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1014-E1021.	3.6	27
216	Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporosis International, 2008, 19, 1247-1250.	3.1	26

#	Article	IF	CITATIONS
217	Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology, 2017, 56, 1167-1176.	1.9	26
218	Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporosis International, 2018, 29, 1505-1510.	3.1	26
219	Targeted education improves the very low recognition of vertebral fractures and osteoporosis management by general internists. Osteoporosis International, 2006, 17, 965-970.	3.1	25
220	Calcitropic Hormones and IGF-I Are Influenced by Dietary Protein. Endocrinology, 2011, 152, 1839-1847.	2.8	25
221	Prevalence of vertebral fracture in oldest old nursing home residents. Osteoporosis International, 2012, 23, 2601-2606.	3.1	25
222	In vitro bone exposure to strontium improves bone material level properties. Acta Biomaterialia, 2013, 9, 7005-7013.	8.3	24
223	Low Protein Intake Is Associated With Impaired Titanium Implant Osseointegration. Journal of Bone and Mineral Research, 2005, 21, 258-264.	2.8	23
224	Systemic Treatment with Strontium Ranelate Accelerates the Filling of a Bone Defect and Improves the Material Level Properties of the Healing Bone. BioMed Research International, 2014, 2014, 1-10.	1.9	23
225	The global approach to rehabilitation following an osteoporotic fragility fracture: A review ofÂthe rehabilitation working group of the International Osteoporosis FoundationÂ(IOF) committee of scientific advisors. Osteoporosis International, 2022, 33, 527-540.	3.1	23
226	Physiology of Calcium and Phosphate Homeostases. , 2006, , 345-360.		22
227	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion, 2015, 31, 1041-1045.	1.9	22
228	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 2016, 28, 1-16.	2.9	22
229	Serum Levels of a Cathepsin-K Generated Periostin Fragment Predict Incident Low-Trauma Fractures in Postmenopausal Women Independently of BMD and FRAX. Journal of Bone and Mineral Research, 2017, 32, 2232-2238.	2.8	21
230	Acquisition of peak bone mass. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101616.	4.7	21
231	Stimulation by parathyroid hormone-related protein and transforming growth factor-α of phosphate transport in osteoblast-like cells. Journal of Bone and Mineral Research, 1991, 6, 1235-1242.	2.8	20
232	Strontium ranelate stimulates trabecular bone formation in a rat tibial bone defect healing process. Osteoporosis International, 2017, 28, 3475-3487.	3.1	20
233	Interaction between LRP5 and periostin gene polymorphisms on serum periostin levels and cortical bone microstructure. Osteoporosis International, 2018, 29, 339-346.	3.1	20
234	Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric, 2015, 18, 805-812.	2.4	19

#	Article	IF	Citations
235	Selective osteoblast overexpression of IGF-I in mice prevents low protein-induced deterioration of bone strength and material level properties. Bone, 2011, 49, 1073-1079.	2.9	18
236	Effect of dexamethasone on parathyroid hormone stimulation of cyclic AMP in an opossum kidney cell line. Journal of Cellular Physiology, 1987, 132, 517-523.	4.1	16
237	Pamidronate Prevents Bone Loss and Decreased Bone Strength in Adult Female and Male Rats Fed an Isocaloric Low-Protein Diet. Journal of Bone and Mineral Research, 2005, 20, 1365-1371.	2.8	16
238	Selective Determinants of Low Bone Mineral Mass in Adult Women with Anorexia Nervosa. International Journal of Endocrinology, 2013, 2013, 1-9.	1.5	16
239	Nutrition and Sarcopenia. Journal of Clinical Densitometry, 2015, 18, 483-487.	1.2	16
240	Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein. Bone, 1992, 13, 321-325.	2.9	15
241	Alterations of calcium and phosphate metabolism in primary hyperparathyroidism during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1993, 72, 488-492.	2.8	15
242	Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 3-16.	2.7	15
243	Cyclic AMP increases the release of parathyroid hormone-related protein from a lung-cancer cell line. International Journal of Cancer, 1994, 56, 422-426.	5.1	14
244	Long-term Outcome of Weekly Bisphosphonates. Clinical Orthopaedics and Related Research, 2006, 443, 61-65.	1.5	14
245	Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology, 2021, 28, 100361.	2.4	14
246	Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. Aging Clinical and Experimental Research, 2022, 34, 481-483.	2.9	14
247	Calcium absorption in rat large intestine in vivo: availability of dietary calcium. American Journal of Physiology - Renal Physiology, 1986, 251, G14-G18.	3.4	13
248	Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women. Osteoporosis International, 2015, 26, 383-393.	3.1	13
249	Outcome Priorities for Older Persons With Sarcopenia. Journal of the American Medical Directors Association, 2020, 21, 267-271.e2.	2.5	13
250	8 Management of disorders of calcium homoeostasis. Bailliere's Clinical Endocrinology and Metabolism, 1992, 6, 129-142.	1.0	12
251	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. European Geriatric Medicine, 2016, 7, 519-525.	2.8	12
252	FRAX and ethnicity. Osteoporosis International, 2020, 31, 2063-2067.	3.1	12

#	Article	IF	CITATIONS
253	Effect of thyroparathyroidectomy of calcium metabolism in rats: role of 1,25-dihydroxyvitamin D3 American Journal of Physiology - Endocrinology and Metabolism, 1977, 233, E160.	3.5	11
254	Determinants of peak bone mass. Annales D'Endocrinologie, 2006, 67, 114-115.	1.4	11
255	Low Calcium-Phosphate Intakes Modulate the Low-Protein Diet-Related Effect on Peak Bone Mass Acquisition: A Hormonal and Bone Strength Determinants Study in Female Growing Rats. Endocrinology, 2014, 155, 4305-4315.	2.8	11
256	Influence of a fermented protein-fortified dairy product on serum insulin-like growth factor-l in women with anorexia nervosa: A randomized controlled trial. Clinical Nutrition, 2016, 35, 1032-1038.	5.0	11
257	Effect of pertussis toxin on parathyroid hormone-stimulated cyclic AMP production in cultured kidney cells. Journal of Bone and Mineral Research, 1988, 3, 605-609.	2.8	10
258	The gaps between patient and physician understanding of the emotional and physical impact of osteoporosis. Archives of Osteoporosis, 2010, 5, 145-153.	2.4	10
259	Effect of Hydrochlorothiazide on 1,25-dihydroxyvitamin D3-induced Changes in Calcium Metabolism in Experimental Hypoparathyroidism in Rats. Clinical Science, 1981, 60, 101-107.	4.3	9
260	Osteoporosis: non-hormonal treatment. Climacteric, 2007, 10, 74-78.	2.4	9
261	Prepubertal Impact of Protein Intake and Physical Activity on Weight Bearing Peak Bone Mass and Strength in Males. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2449.	3.6	9
262	Associations between age-related changes in bone microstructure and strength and dietary acid load in a cohort of community-dwelling, healthy men and postmenopausal women. American Journal of Clinical Nutrition, 2020, 112, 1120-1131.	4.7	9
263	Indications to teriparatide treatment in patients with osteoporosis. Swiss Medical Weekly, 2011, 141, w13297.	1.6	9
264	Physiology of Calcium and Phosphate Homeostases. , 2006, , 345-360.		8
265	Administration of growth hormone in selectively protein-deprived rats decreases BMD and bone strength. Bone, 2010, 46, 1574-1581.	2.9	8
266	Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients. European Journal of Endocrinology, 2014, 170, 441-450.	3.7	8
267	Selective protein depletion impairs bone growth and causes liver fatty infiltration in female rats: prevention by Spirulina alga. Osteoporosis International, 2016, 27, 3365-3376.	3.1	8
268	Microbiota and Bone Health: The Gut-Musculoskeletal Axis. Calcified Tissue International, 2018, 102, 385-386.	3.1	8
269	Fracture Risk Following an Atypical Femoral Fracture. Journal of Bone and Mineral Research, 2020, 37, 87-94.	2.8	8
270	Long-term strategy in the management of postmenopausal osteoporosis. Joint Bone Spine, 2007, 74, 540-543.	1.6	7

#	Article	IF	CITATIONS
271	Management of the oldest old with osteoporosis. European Geriatric Medicine, 2010, 1, 15-21.	2.8	7
272	A critical pathway for the management of elderly inpatients with malnutrition: effects on serum insulin-like growth factor-I. European Journal of Clinical Nutrition, 2013, 67, 1175-1181.	2.9	7
273	Higher rates of osteoporosis treatment initiation and persistence in patients with newly diagnosed vertebral fracture when introduced in inpatients than later in outpatients. Osteoporosis International, 2019, 30, 1353-1362.	3.1	7
274	Osteoporosis: Treatment Gaps and Health Economics. , 2019, , 288-295.		7
275	A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCEO working group. Seminars in Arthritis and Rheumatism, 2020, 50, 859-866.	3.4	7
276	Microarchitecture in focus. Osteoporosis International, 2010, 21, 403-406.	3.1	6
277	Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2012, 23, 193-199.	3.1	6
278	Occupation-dependent loading increases bone strength in men. Osteoporosis International, 2016, 27, 1169-1179.	3.1	6
279	How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?. Osteoporosis International, 2021, 32, 1921-1935.	3.1	6
280	Transforming growth factor-beta modulates the parathyroid hormone- related protein-induced responses in renal epithelial cells. Endocrinology, 1993, 133, 145-151.	2.8	6
281	Associations of Calcium Intake and Calcium from Various Sources with Blood Lipids in a Population of Older Women and Men with High Calcium Intake. Nutrients, 2022, 14, 1314.	4.1	6
282	Towards a better management of glucocorticoid-induced osteoporosis?. Nature Reviews Rheumatology, 2017, 13, 635-636.	8.0	5
283	Actions of parathyroid hormone and parathyroid hormone-related protein. Journal of Endocrinological Investigation, 1992, 15, 51-6.	3.3	5
284	Hypoparathyroidism Associated with Aneurysm of the Left Subclavian Artery (Kommerell's) Tj ETQq0 0 0 rgBT /Ov Research, 2001, 16, 1926-1928.	erlock 10 2.8	Tf 50 227 To 4
285	A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women — Study protocol. Trials, 2008, 9, 19.	1.6	3
286	Relationship between bone mineral content and bone turnover markers, sex hormones and calciotropic hormones in pre- and early pubertal children. Osteoporosis International, 2020, 31, 335-349.	3.1	3
287	Effects of lectins and tunicamycin on cAMP response to parathyroid hormone. American Journal of Physiology - Endocrinology and Metabolism, 1989, 256, E80-E86.	3.5	2
288	Determination of circulating parathyroid hormone levels and differential diagnosis of hypercalcemia. Nuclear Medicine and Biology, 1994, 21, 337-347.	0.6	2

#	Article	IF	Citations
289	Long-Term Use of Bisphosphonates in Osteoporosis. Women's Health, 2006, 2, 309-315.	1.5	2
290	A Low Protein Diet Alters Bone Material Level Properties and the Response toln VitroRepeated Mechanical Loading. BioMed Research International, 2014, 2014, 1-6.	1.9	2
291	CAPTURE THE FRACTURE: INTEGRATED CARE PREVENTS THE DECREASE IN INTRINSIC CAPACITY IN ELDERLY SUBJECTS. Innovation in Aging, 2017, 1, 692-692.	0.1	2
292	Diet, Microbiota, and Bone Health., 2019, , 143-168.		2
293	Histoâ€anatomy of the proximal femur in rats: Impact of ovariectomy on bone mass, structure, and stiffness. The Anatomical Record, 1996, 245, 633-644.	1.8	2
294	Determinants of Peak Bone Mass Acquisition. Contemporary Endocrinology, 2020, , 115-137.	0.1	2
295	Osteoporosis in men. Nursing Clinics of North America, 2001, 36, 467-79, ix.	1.5	2
296	Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative. Archives of Osteoporosis, 2022, 17, 5.	2.4	2
297	Yogurt Consumption and Impact on Bone Health. , 2017, , 507-524.		1
298	Strontium Ranelate in the Prevention of Osteoporotic Fractures. , 2013, , 1935-1947.		0
299	Are Bisphosphonates Associated With an Increased Risk of Atypical Femoral Fractures as a Class?—Reply. JAMA Internal Medicine, 2013, 173, 79.	5.1	О
300	Reply to D Xie and Z Sheng. American Journal of Clinical Nutrition, 2017, 106, 322-323.	4.7	0
301	IMPACT OF DIABETES ON THE PREVALENCE OF MALNUTRITION AND SARCOPENIA IN AGED HOSPITALIZED PATIENTS. Innovation in Aging, 2017, 1, 149-150.	0.1	0
302	Focal and Osteosclerotic Bone Diseases. Calcified Tissue International, 2019, 104, 481-482.	3.1	0
303	Hypercalcemia: Other Causes than Primary Hyperparathyroidism. , 2019, , 160-167.		0
304	Nutrition and bone disease., 2020,, 523-533.		0
305	In memory of Harry K Genant. Osteoporosis International, 2021, 32, 607-608.	3.1	0
306	Reference microarchitectural values measured by HR-pQCT in a Franco-Swiss cohort of young adult women. Osteoporosis International, 2022, 33, 703-709.	3.1	0

#	Article	IF	CITATIONS
307	Prevention of Osteoporosis and Fragility Fractures. , 2019, , 31-42.		0
308	Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporosis International, 2022, , 1.	3.1	0